Regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art Restylane syringe for use with its Restylane NASHA lidocaine products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.

The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners. It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients.

“Developing this new syringe in close collaboration with practitioners to address their specific needs has really set it apart” said Dr. Luddi Luiz Oliveira, Brazilian plastic surgeon, in the release. “Repetitive hand movements like performing numerous injections every day can lead to strain and reduced mobility, but the syringe’s ergonomic design, with a cushioned finger grip and thumb rest ensure maximum comfort when injecting, supporting consistent, high quality results for patients.” 

Designed in collaboration with over 70 aesthetics practitioners, the next-generation Restylane syringe was optimized for ergonomic functionality, ease of aspiration, ease of operation, and a premium look and feel, resulting in an innovative syringe that supports practitioners with delivering premium results.  Additionally, the syringe was designed with sustainability in mind, with compact paper-only carton packaging that is 100% recyclable and reduces in-clinic waste by up to 30% based on volume reduction. 

Galderma’s versatile Restylane portfolio is the only hyaluronic acid (HA) range offering four distinct technologies, NASHA, NASHA HD, OBT, and SB-NASHA, that offer firmer gels that provide contouring and structural support, to soft, flexible formulations that smooth facial lines and wrinkles for a more youthful look. With HA closest to the skin’s own, it is designed to deliver personalized, natural-looking outcomes that provide contour, definition, and hydration, meeting diverse patient needs across key areas of the face, décolletage, and in the hands. The new state-of-the-art syringe represents the next step in Restylane’s evolution, with a novel way to deliver its trusted premium results.  

“This next-generation syringe reflects the latest advancements in injection design, giving aesthetic practitioners greater precision, improved ergonomics, and enhanced control,” said Baldo Scassellati Sforzolini, MD, PhD, Global Head of R&D at Galderma, in the release. “By refining every element of the injector experience, we aim to help clinicians deliver consistently premium results for their patients. Through direct collaboration with practitioners, Galderma continues to push the boundaries of aesthetic innovation, and we remain steadfast in our commitment to driving the field forwards."

The next-generation syringe is now approved for use in the EU, the U.S., and Canada with the NASHA lidocaine range of Restylane products including, Restylane Lyft Lidocaine, Restylane Eyelight and Restylane-L (known as Classyc Lidocaine in some markets).

With over 30 years of innovation and more than 77 million treatments administered worldwide, Restylane’s has an iconic heritage as a trusted, science-backed HA treatment that consistently delivers premium results. Building on this heritage, the new state-of-the-art Restylane syringe demonstrates Galderma’s continued innovation, and solidifies its position at the forefront of aesthetics. 

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. It delivers an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since its foundation in 1981, Galderma has dedicated its focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because Galderma understands that the skin we are in shapes our lives, the company is advancing dermatology for every skin story. For more information: www.galderma.com.